



**BUREAU OF NATUROPATHIC MEDICINE**  
 1625 North Market Blvd., Suite S-209  
 Sacramento, CA 95834  
 (916) 574-7991 – Office / (916) 574-8645 - FAX



**NATUROPATHIC FORMULARY ADVISORY COMMITTEE**  
**Meeting Minutes**  
 July 23, 2006

**COMMITTEE MEMBERS  
 PRESENT:**

Peter Wannigman, Naturopathic Doctor  
 (Chairman)  
 Soram Khalsa, Medical Doctor (Vice  
 Chair)  
 Cynthia Watson, Medical Doctor  
 Trevor Holly Cates, Naturopathic Doctor  
 Michael Traub, Naturopathic Doctor  
 Paul Mittman, Naturopathic Doctor  
 Larry Woodhouse, Pharmacist

**COMMITTEE MEMBERS  
 ABSENT:**

Mary Hardy, Medical Doctor  
 Arthur Presser, Pharmacist

**STAFF PRESENT:**

Linda Brown  
 Tonya Blood

**I. Call to Order and Roll Call**

Chairman Wannigman called the meeting to order. Roll call was taken and a quorum was present.

**II. Approval of the June 4, 2006 Meeting Minutes**

Dr. Khalsa made a motion that the minutes be approved as written. Dr. Cates seconded the motion. Roll was called and the minutes were approved as written.

**III. Chairperson's Report**

- Chairman Wannigman asked if the opinion from the Pharmacy Board had been received and Tonya reported that the Bureau had not yet received it.
- Linda reported that she had received a letter from NCMIC stating that there were no claims against NDs for prescribing.
- Dr. Mittman is working on "Why NDs need to Prescribe" and will have it completed by the next meeting.

The Medical Board was asked to comment. Linda Whitney, Director of Legislation for the Medical Board, reported that two members of the Medical Board had a task force meeting for discussion of the ND formulary. The task force had some concerns and issues with what the protocols and procedures would be that an ND would follow and that should be addressed in more detail as far as what would be done in terms of reducing medication or changing prescriptions. She recommended a thoroughly developed white paper on why NDs want to prescribe,

when they would, and when they would make recommendations on changing prescriptions.

There was discussion that NDs should work with MDs in collaboration to reduce medication or get a patient off of a medication.

- Dr. Khalsa will check with his malpractice company regarding the charge or surcharge for supervising an ND.

#### **IV. Bureau Report**

The Bureau now has 191 licensed NDs. They do not have the budget figures yet for the end of the year. There was nothing further to report.

#### **V. Discussion, Review, and Approval of IV Formulary**

Dr. Virginia Osborne and the committee discussed research and the safety of glandulars – particularly thymus and adrenal. The committee decided to review the documents and research before taking a vote at the next meeting. Any documents on adrenal and thymus should be emailed to Linda Brown for distribution.

#### **VI. Discussion and Approval of 60-hour Course for Enhanced Prescribing Rights**

The course modules were reviewed and the committee voted to approve successful completion of the course (or its equivalent) as continuing education required for enhanced independent prescribing rights for California NDs. It was discussed that the course is available on CDs for \$1200. Dr. Traub made a motion to approve the 60-hour course for enhanced independent prescribing rights, using the four modules that were used in Arizona. Dr. Cates seconded the motion. Dr. Khalsa commented that when the recommendations hit the statutory realm that they will probably be shot down by CMA and others. Dr. Watson commented that the course alone would not make NDs proficient at prescribing that many drugs. Dr. Traub commented that prescribing medications is included in the current curriculum of the naturopathic medical schools. The main concern is for individuals that graduated a long time ago who did not have pharmacology so that they can have the knowledge they need to safely prescribe. Roll was called and the motion passed. Dr. Khalsa made a motion that an examination needs to be passed, in a continuing education format, to allow credit for this course for enhanced independent prescribing rights. Dr. Cates seconded the motion. Roll was called and the motion was passed.

## **VII. Discussion and Approval of Inclusionary/Exclusionary Pharmaceutical Formulary for Recommendation**

Dr. Khalsa asked Tonya to give him a contact at CMA that he could call and discuss what the committee has been working on.

The committee reviewed the last category, Respiratory Agents. Lung Surfactants were added to the exclusionary list.

Dr. Wannigman pointed out that the final inclusionary formulary is 5 pages long and the exclusionary formulary is less than one and a half pages. Dr. Traub made a motion that the exclusionary list be approved. Dr. Cates second the motion. Roll call was taken and the motion was passed.

Dr. Wannigman stated that if the exclusionary formulary becomes law then there would be a problem when a new drug comes out because it would not be approved for use by NDs until it has been reviewed. He suggested that the Bureau purchase and maintain a subscription to the online Drug Facts and Comparisons so they could identify when a new drug comes online. It was stated that the Advisory Council or a committee of the Bureau should seek to have legal authority to review and update the formulary annually.

## **VIII. Discussion and Approval of Recommendation of Additional Formulary for NDs Meeting the Current Prescribing Requirements**

Linda stated that the Bureau would like the committee to consider as part of the recommendations developing a small inclusionary list that NDs having the current requirement of 48 hours of pharmacology could prescribe in addition to the hormones and epinephrine allowed by existing law. There was discussion that because of opposition from the medical community the proposed exclusionary list may not be a workable plan and that something more conservative would have a better change of getting through. Dr. Wannigman asked for volunteers to work on the list within the next 3 weeks and send the list out to everyone for approval at the next meeting. Drs. Watson, Woodhouse, and Traub will be working on this.

## **IX. Future Meeting Dates**

The next meeting will be by teleconference on Tuesday, August 29, 2006 at 5:30 p.m. A follow-up meeting date was set for September 11 at 6:00 p.m.

## **X. Public Comment**

Dr. Gina Nick made comments about glandulars. She said she had a lot of research on using IV thymus extract IV and said she would be happy to provide the information to the committee. She also stated that she was not aware of any other healthcare practitioners that are trained in using IV glandulars and that patients should not be limited access to these highly effective therapies.

## **XI. Adjournment**

The meeting was adjourned.